1. Clinical Mission & Diagnostic Triage Overview
Medicus Labs™ was founded by Mallikarjun R to address the global shortage of dermatological specialists, where over 3 billion people face prolonged clinical waiting lists for routine cutaneous triage. By combining state-of-the-art vision transformer neural architectures with multi-center clinical datasets (including the International Skin Imaging Collaboration [ISIC], HAM10000, and DermNet clinical registries), our platform delivers probabilistic pre-screening insights, severity stratifications, and downloadable 1-page Clinical Intake Summaries for patient-doctor consultations.
Our algorithms evaluate lesion border symmetry, pigment distribution variegation, follicular plug congestion, and vascular erythema patterns to differentiate benign from potentially malignant cutaneous presentations.
2. Peer-Referenced Clinical Dermatology Library (34 Comprehensive Guides)
All clinical articles are authored and peer-referenced under the editorial direction of Mallikarjun R and the Medicus Labs Medical Advisory Board, aligned with WHO ICD-11 pathology standards:
Inflammatory & Acneiform Dermatoses:
- Acne Vulgaris (ICD-11: 8A40 / DA01) — Pathophysiology, Grade I-IV severity grading, C. acnes colonization, and topical retinoid therapeutics.
- Rosacea Subtypes (ICD-11: ED90) — Centrofacial erythema, Demodex mite etiology, neurovascular triggers, and topical ivermectin.
- Acne Vulgaris vs. Rosacea Differential — Comedone markers vs. telangiectatic flushing, misdiagnosis prevention, and tailored protocols.
- Perioral Dermatitis — Topical steroid rebound, follicular pustules, zero-therapy guidelines, and oral tetracyclines.
- Hidradenitis Suppurativa (ICD-11: ED92) — Intertriginous sinus tracts, Hurley staging I-III, and anti-TNF biologics.
- Folliculitis (Bacterial & Pityrosporum) — S. aureus vs. Malassezia fungal hair follicle infection and antimicrobial washes.
Eczematous, Autoimmune & Scaling Dermatoses:
- Atopic Dermatitis & Eczema (ICD-11: EA80) — FLG filaggrin barrier mutations, SCORAD severity index, ceramides, and dupilumab.
- Contact Dermatitis (Irritant vs. Allergic) — Type IV delayed hypersensitivity, patch test protocols, and allergen avoidance.
- Seborrheic Dermatitis — Malassezia yeast proliferation, scalp and nasolabial cradle cap/scaling, and zinc pyrithione.
- Plaque Psoriasis (ICD-11: EA90) — Th17/IL-23 cytokine signaling, Auspitz bleeding sign, PASI score, and IL-17 inhibitors.
- Alopecia Areata (ICD-11: ED70) — Autoimmune T-cell hair follicle destruction, exclamation-point hairs, and JAK inhibitors.
- Vitiligo (ICD-11: ED63) — Autoimmune melanocyte destruction, Wood's lamp examination, and narrow-band UVB phototherapy.
Cutaneous Oncology & Pre-Malignant Neoplasms:
- Cutaneous Melanoma (ICD-11: 2C30) — ABCDE diagnostic criteria, Breslow invasion depth, dermoscopic blue-white veil, and wide excision.
- Basal Cell Carcinoma (BCC) (ICD-11: 2C32) — Pearly rolled borders, arborizing telangiectasias, ulceration, and Mohs micrographic surgery.
- Squamous Cell Carcinoma (cSCC) (ICD-11: 2C31) — Hyperkeratotic exophytic nodules, sun-exposed fields, and metastatic risk staging.
- Actinic Keratosis (Pre-Cancerous AK) — UV-induced intraepidermal keratinocyte dysplasia and topical 5-fluorouracil field therapy.
- Dysplastic (Atypical) Nevi — Atypical mole syndrome, architectural disorder, and serial digital dermoscopy surveillance.
- Keratoacanthoma — Rapidly growing crateriform lesions with central keratin plugs and differentiation from SCC.
- Seborrheic Keratosis — Benign epidermal proliferations with "stuck-on" greasy appearance and cryoablation options.
- Skin Tags (Acrochordons) — Benign fibrovascular papillomas, insulin resistance links, and sterile clinical excision.
Infectious, Viral, Fungal & Pigmentary Conditions:
- Tinea Corporis & Ringworm (ICD-11: 1F28) — Trichophyton rubrum annular scaling plaques, KOH prep, and terbinafine.
- Tinea Versicolor (Pityriasis) — Malassezia furfur dimorphism, hypopigmentation, and selenium sulfide therapy.
- Tinea Pedis (Athlete's Foot) — Macerated interdigital fissures, moccasin distribution, and barrier hygiene.
- Onychomycosis (Fungal Nail Infection) — Subungual hyperkeratosis, nail plate dystrophy, and oral pulse antifungals.
- Herpes Zoster (Shingles) (ICD-11: 1E91) — Varicella zoster reactivation, dermatomal painful vesicles, and early valacyclovir.
- Molluscum Contagiosum (ICD-11: 1E70) — Poxvirus umbilicated pearly papules, autoinoculation prevention, and spontaneous resolution.
- Impetigo (ICD-11: 1B70) — Contagious superficial pyoderma, honey-colored serous crusts, and topical mupirocin.
- Melasma — Centrofacial hormonal hyperpigmentation, estrogen receptor sensitivity, and physical iron oxide sunscreen.
- Post-Inflammatory Hyperpigmentation (PIH) — Post-injury melanocyte hyperactivity, tyrosinase inhibitors, and azelaic acid.
- Evidence-Based Dermatological Skincare — Double-blind trials for retinoids, niacinamide, L-ascorbic acid, and ceramides.
- Comprehensive Retinoids Guide — Tretinoin, adapalene, tazarotene, and retinoic acid receptor cellular mechanisms.
- Oily & Blemish-Prone Skin Protocol — Sebaceous gland regulation, 2% salicylic acid, and barrier-safe hydration.
- How AI Analyzes Cutaneous Lesions — Vision transformers, spatial attention heatmaps, and false-positive reduction.
- When to Visit a Licensed Dermatologist — Red flag symptoms, ulceration, rapid evolution, and diagnostic triage.
3. Editorial Governance, E-E-A-T & Medical Citations
Medicus Labs strictly adheres to the Oxford Centre for Evidence-Based Medicine evidence hierarchy. Every recommendation is cross-referenced with peer-reviewed medical publications, including the Journal of the American Academy of Dermatology (JAAD), The Lancet, British Journal of Dermatology (BJD), and guidelines from the American Academy of Dermatology (AAD).
Read our full governance framework at our Medical Editorial Policy and author transparency on our About Medicus page.
4. Google AdSense & Advertising Compliance Disclosures
In compliance with Google Publisher Policies, Medicus Labs partners with Google AdSense (Publisher ID: ca-pub-8305972358699914) to serve non-intrusive contextual advertising. Third-party vendors, including Google, use cookies (such as DoubleClick DART cookies) to serve advertisements based on user browsing history. Users may opt out of personalized advertising by visiting Google Ads Settings or aboutads.info.
Under our HIPAA-aligned patient privacy charter, no uploaded skin images or diagnostic outputs are ever shared with advertisers or third-party ad tracking networks. View our full Privacy Policy.
Clinical & Emergency Medical Disclaimer
Medicus Labs™ is an artificial intelligence pre-screening and educational health platform. It is not a medical device and does not provide formal medical diagnoses or prescriptions. Reports and analysis metrics do not replace in-person examination by a board-certified dermatologist. In an acute emergency, please contact local emergency medical services immediately.